EGFR and lung cancer: EML4-ALK, EGFR, and KRAS mutations were all mutually exclusive, suggesting that ALK mutation may be an important oncogenic factor, and a potential therapeutic target in EGFR wild-type and KRAS wild-type lung cancer.